SavedAdd your journal

Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2021 / Cilt: 34 - Sayı: 1

Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder

Ali ERDOĞAN
Burak KULAKSIZOĞLU
Mert Sinan BİNGÖL
Buket CİNEMRE
Mehmet Murat KULOĞLU
Pages
102–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These case reports suggest that LAIAM treatment might be an effective and safe treatment option in SIPD and reduce substance craving.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years, the rate of substance-induced psychotic disorder (SIPD) has been gradually increasing.
📊
Key Findings & Data:Novel depot antipsychotic treatments, such as long-acting injectable aripiprazole monohydrate 400 mg (LAIAM) are reported to improve treatment compliance and functionality in psychotic disorders.
💡
Conclusion & Impact:These case reports suggest that LAIAM treatment might be an effective and safe treatment option in SIPD and reduce substance craving.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

In recent years, the rate of substance-induced psychotic disorder (SIPD) has been gradually increasing. Non-compliance with treatment and substance craving are serious problems in SIPD. Novel depot antipsychotic treatments, such as long-acting injectable aripiprazole monohydrate 400 mg (LAIAM) are reported to improve treatment compliance and functionality in psychotic disorders. However, the number of studies showing the efficacy of LAIAM treatment in patients with dual diagnosis is limited. In this paper, we present two cases. The first case was diagnosed with SIPD and the other was diagnosed with psychotic disorder with a past history of profound substance use disorder. The two cases showed both clinical and functional improvement at 1-year follow-up after the initiation of LAIAM treatment. These case reports suggest that LAIAM treatment might be an effective and safe treatment option in SIPD and reduce substance craving.

🔖

Cite This Article

ERDOĞAN, A., KULAKSIZOĞLU, B., BİNGÖL, M. S., CİNEMRE, B., KULOĞLU, M. M. (2021). Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 34 - Sayı: 1, 102–106. https://ajindex.com/articles/218443

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology 2014; 83:1-8
  2. Tenn CC, Fletcher PJ, Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 2003; 64:103-114
  3. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012; 42:1321-1328
  4. American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013
  5. Wilson L, Szigeti A, Kearney A, Clarke M. Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: A systematic review. Schizophr Res 2018; 197:78-86
  6. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med 2003; 33:1149-1160
  7. Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21:754-768
  8. Chue P, Chue J. A review of aripiprazole long-acting injection. Curr Med Res Opin 2016; 32:441-452
  9. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005; 25:363-366
  10. Beresford T, Buchanan J, Thumm EB, Emrick C, Weitzenkamp D, Ronan PJ. Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence. J Clin Psychopharmacol 2017; 37:657-663
  11. Meini M, Moncini M, Cecconi D, Cellesi V, Biasci L, Simoni G, et al. Safety, tolerability, and self-rated effects of aripiprazole and ropinirole treatment for cocaine dependence: a pilot study. Am J Addict 2011; 20:179-180
  12. Montemitro C, Baroni G, Cantelmi V, Tittozzi B, Pettoruso M, Di Nicola M, et al. Long-acting injectable aripiprazole as treatment for psychiatric patients comorbid with substance-related and addictive disorder: efficacy and safety. Eur Neuropsychopharmacol 2017; 27:1072
  13. Chen SF, Shen YC. Long-acting injectable aripipra